Holen Sie sich die Stockscreener-App
13.49
1.75%
-0.24
Handel nachbörslich:
13.36
-0.13
-0.96%
Schlusskurs vom Vortag:
$13.73
Offen:
$13.61
24-Stunden-Volumen:
1.06M
Relative Volume:
0.90
Marktkapitalisierung:
$957.03M
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-2.852
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
-0.37%
1M Leistung:
+10.48%
6M Leistung:
+388.77%
1J Leistung:
-28.78%
1-Tages-Spanne:
$13.25
$14.22
1-Wochen-Bereich:
$13.02
$16.08
52-Wochen-Spanne:
$2.21
$19.05
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
13.49 | 976.73M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
Phathom Pharmaceuticals begins Phase 2 trial of VOQUEZNA for eosinophilic esophagitis - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Begins Phase 2 Trial for Eosinoph - GuruFocus
Phathom (NASDAQ: PHAT) doses first patient in Phase 2 EoE trial, enrolling 80 adults - Stock Titan
Phathom Pharmaceuticals Begins Phase 2 EoE Trial - TipRanks
Phathom Pharmaceuticals Initiates Phase 2 EoE Clinical Trial - TradingView
What margin trends mean for Phathom Pharmaceuticals Inc. stockWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Is Phathom Pharmaceuticals Inc. stock a buy on dipsAnalyst Upgrade & High Accuracy Swing Trade Signals - newser.com
Volatility clustering patterns for Phathom Pharmaceuticals Inc.Portfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Momentum Check & Stock Portfolio Risk Management - newser.com
Will Phathom Pharmaceuticals Inc. stock see PE expansionForecast Cut & High Win Rate Trade Alerts - newser.com
How strong is Phathom Pharmaceuticals Inc. stock revenue growth2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Phathom Pharmaceuticals (Nasdaq: PHAT) to join 5 investor conferences; 90‑day webcasts - Stock Titan
Is Phathom Pharmaceuticals Inc. a candidate for recovery playMarket Performance Report & Daily Stock Momentum Reports - newser.com
Why Phathom Pharmaceuticals Inc. stock remains a top recommendationProduct Launch & Safe Entry Point Alerts - newser.com
Can Phathom Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Big Picture & Real-Time Volume Analysis Alerts - newser.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
Can Phathom Pharmaceuticals Inc. recover in the next quarterPortfolio Return Report & Long-Term Safe Investment Ideas - newser.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
AlphaQuest LLC Buys 30,760 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap UpTime to Buy? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Phathom Pharmaceuticals Inc. stock rally after Fed decisions2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Price action breakdown for Phathom Pharmaceuticals Inc.Portfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges - TipRanks
Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 8.9% on Strong Earnings - MarketBeat
HC Wainwright & Co. Raises Price Target for PHAT to $26.00 | PHA - GuruFocus
Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim - Investing.com Australia
How sentiment analysis helps forecast Phathom Pharmaceuticals Inc.Quarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Phathom Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Phathom Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):